Visit G1 Therapeutics' exhibit today!

Find out about G1 Therapeutics' clinical trials and R&D pipeline

Click here to see COSELA’s Mechanism of Action

Access information about COSELA and G1 Therapeutics' resources

Learn more about why G1 Therapeutic’s mission is to discover, develop, and deliver next generation therapies that improve the lives and outcomes of people living with cancer

G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and delivery of next generation therapies that improve the lives of those affected by cancer, including the company’s first commercially available product COSELA™ (trilaciclib), a first-in-class therapy approved by the U.S. Food and Drug Administration to help protect against chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer being treated with chemotherapy. Trilaciclib is also being evaluated in other solid tumors, including colorectal, breast and bladder cancers. For additional information, please visit www.g1therapeutics.com.

Our mission is to develop and deliver innovative therapies that improve the lives of those affected by cancer. Led by a team with a deep understanding of the biology of cancer and extensive drug discovery, development and commercialization experience, we are rapidly advancing two novel therapies for people living with cancer.

COSELA™ (trilaciclib) is a first-in-class therapy designed to improve outcomes for people with cancer who are treated with chemotherapy. G1 is also advancing rintodestrant, a potential best-in-class oral selective estrogen receptor degrader, or SERD, for the treatment of ER+ breast cancer. In 2020, G1 out-licensed global development and commercialization rights to its differentiated oral CDK4/6 inhibitor, lerociclib.